菜单
Designs clinical trial monitoring dashboards and tracking frameworks for enrollment, protocol adherence, safety reporting, and regulatory milestones. Outputs a trial tracking specification with KPIs and alert thresholds.
默认使用会先检查来源的 Prompt；你也可以切换为直接命令，或下载本地副本。
决定是否安装前，请先阅读 SKILL.md，以及 SkillsMP 当前展示的配套文件。
用 Codex 或 Claude 帮你安装 复制这段 Prompt，粘贴到 Codex、Claude 或其他助手里，让它检查 Skill 页面并帮你完成安装。
直接命令不会经过审查 Prompt；运行前请先检查来源。
npx skills add https://github.com/UitbreidenOS/UitKit --skill clinical-trial-tracker命令会保持在同一行。复制前请横向滚动并检查完整内容。
想先保存到本地？可下载 SkillsMP 当前能够提供的文件。
正在显示 SKILL.md
Guidelines and instructions for Agent execution state rollback rules
Guidelines and instructions for Agent execution step counters limits
Guidelines and instructions for Agent execution timeout limits setups
基于 SOC 职业分类
| name | clinical-trial-tracker |
| description | Designs clinical trial monitoring dashboards and tracking frameworks for enrollment, protocol adherence, safety reporting, and regulatory milestones. Outputs a trial tracking specification with KPIs and alert thresholds. |
| allowed-tools | Read, Write, WebSearch |
| effort | high |
When setting up monitoring for a new clinical trial, when an existing trial has enrollment or protocol deviation concerns, or when preparing for a regulatory audit or DSMB review. Use for Phase I-IV trials across all therapeutic areas.
Skip for pre-clinical (animal) studies (use bio_research_stack), retrospective chart reviews without prospective tracking, or when the trial monitoring framework is already operational and meeting all KPIs.
Trial design parameters:
Enrollment tracking:
Protocol adherence:
Safety monitoring:
Regulatory milestones:
TRIAL TRACKER: [Protocol ID] — [Title]
PHASE: [I/II/III/IV] | THERAPEUTIC AREA: [area]
PRIMARY ENDPOINT: [endpoint] | TARGET ENROLLMENT: [N]
ENROLLMENT DASHBOARD:
| Site | Screened | Enrolled | Target | Screen Fail % | Velocity |
|------|----------|----------|--------|---------------|----------|
PROTOCOL DEVIATIONS:
Total: [X] | Major: [X] | Minor: [X]
Rate: [X] per 100 patient-visits
Top types: [list]
SAFETY:
SAEs: [X] | Related: [X] | SUSARs: [X]
Deaths: [X] | Discontinuations (AE): [X]
REGULATORY MILESTONES:
| Milestone | Planned | Actual/Forecast | Status |
|-----------|---------|-----------------|--------|
ALERT THRESHOLDS:
Enrollment: <[X] patients/week → escalate
Screen fail: >[X]% → review criteria
Deviations: >[X] per site → monitoring visit
SAE: Report within [X] hours of awareness
TRIAL TRACKER: PROTOCOL-2026-042 — Phase III Anti-PD-1 in Metastatic NSCLC
PHASE: III | THERAPEUTIC AREA: Oncology (NSCLC)
PRIMARY ENDPOINT: Overall survival (OS) | TARGET ENROLLMENT: 600
ENROLLMENT DASHBOARD:
| Site | Screened | Enrolled | Target | Screen Fail % | Velocity |
|-------------|----------|----------|--------|---------------|-----------|
| MD Anderson | 89 | 52 | 60 | 42% | 3.2/week |
| Mayo Clinic | 67 | 38 | 45 | 43% | 2.8/week |
| UCLA | 45 | 21 | 40 | 53% | 1.5/week |
| Total | 312 | 178 | 600 | 43% | 8.1/week |
PROTOCOL DEVIATIONS:
Total: 23 | Major: 4 | Minor: 19
Rate: 2.1 per 100 patient-visits
Top types: Missed imaging window (8), dose modification without documentation (5)
SAFETY:
SAEs: 34 | Related: 12 | SUSARs: 3
Deaths: 8 (5 disease progression, 2 infection, 1 unknown)
Discontinuations (AE): 14
REGULATORY MILESTONES:
| Milestone | Planned | Actual/Forecast | Status |
|---------------------|------------|-----------------|---------|
| FPFV | 2025-09-01 | 2025-08-28 | ✅ Done |
| Interim analysis | 2026-06-01 | 2026-07-15 | ⚠️ Delay|
| DSMB review #3 | 2026-08-01 | 2026-08-01 | On track|
| LPLV | 2027-03-01 | 2027-06-01 | ⚠️ Risk |
ALERT THRESHOLDS:
Enrollment: <6 patients/week → escalate (CURRENT: 8.1 ✅)
Screen fail: >50% → review criteria (CURRENT: 43% ✅, UCLA 53% ⚠️)
Deviations: >5 per site → monitoring visit
SAE: Report within 24h of awareness